



TWSE 4746

Hope, Passion, Innovation, Sustainability



Disclaimer

This material has been prepared by Formosa Laboratories Inc. ("Formosalab").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herein. The information contained in this presentation is Formosalab' s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of Formosalab. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other

things, management' s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items.

These forwardlooking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.



- Company Profile
- 2023 & 2024 up-to-May Operation Results
- Business Strategy
- Business Update



Company Profile



台耀化學 Formosa Laboratories

Founded
Capital
Market Cap.
Employees
Area
IPO

Business

Focus


29th Dec 1995 36.1 Million USD 370 Million USD 870 45,508 m² March 2011 APIs CDMO for API, HPAPI, injectable, fermentation and peptide



US	Japan	Germany	Mexico	Europe	Taiwan
FDA	-Pmda	BGV	COFEPRIS	edom	Signal
8	21	2	2	1	42
Times	Times	Times	Times	Times	Times
2022	2023	*	*	*	2023


% Taiwan TFDA became a participating authority of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2013.







2024.06 Complete SynChem Acquisition to Expand North America Market






Operation Results



Revenues-2024 YoY 16%



2024/6/12




Revenues-2024 up to May YoY 21%

	Million NTD	YoY
Polymers	676	12%
Respiratory Agents	264	50%
Vit. D Derivatives	251	-27%
CDMO	180	-1%
Anticancer	99	24%
Others	443	129%
Total	1,911	21%




Product Category





Profitability






Business Strategy




Integrated RD and Manufacturing



2024/6/12








Key Business



API Products





Key API Products

- Improve throughput
- Expand manufacture capacity
- Stable supply chain



Highlight

- Polymer products stay strong market share. The new manufacturing facility begins to contribute revenue.
- Respiratory API sales keeps growing on revenue. 2024Q1 begins to contribute revenue.
- Steroid products enter originator' s supply chain and start to deliver to client.
- Vitamin D products keeps single digit growth
- Anti-Cancer products keep contributing revenue from new market and new clients.



Comprehensive CDMO Service-One Stop Shop






Comprehensive CDMO Service-One Stop Shop



- Completes the Acquisition of Synchem to Expand North American CDMO Footprint. A few projects are ongoing
- Clients includes clinical stages and commercial supply in different territories
- Stable CMO supply to originator in Japan, Europe, and US. New projects under discussion
- Multiple projects enter validation and/or commercial manufacturing



Once stop ADC services



Service scope

- Process development
- ADC screening platform
- Scale-up
- Comprehensive analytic services
- Formulation development and manufacturing services

ADC CDMO highlight

- Clients include US, China, Europe, and Taiwan
- Support clients from RD to clinical trial material for Phase I trial.
 Patient enrollment is ongoing. New supply is under discussion.
- New ADC DS and DP has completed and delivered to client for phase I global clinical trial.
- Supply US DMF Eribulin as toxin in the ADC screening platform.
- ADC and peptide conjugation new projects under discussion.



Advanced Technology

- Build up Peptide Synthesis Laboratory with automatic solidphase microwave synthesis for CDMO and Formosa' s product development
- Set up microfluidic reactor for API products and CDMO services







2024/6/12



Injectable Plant Status

- Authority inspection is ongoing
 - Cytotoxic line
 - TFDA: 2022Q2 completed
 - FDA: 2024
 - General line
 - TFDA: 2024
 - FDA: 2025
 - Feasible for biologic and chemical drug product
 - Liquid and Lyo product
 - Clinical trial and commercial scale CDMO services







Self-development Injectable Products

Eribulin Injectable

(Global market size USD 370 million, US Market USD 130 million, TW market NTD 450 million)

Territory	Status
Turkey	Licensing agreement signed
EU	Licensing agreement signed
US	GDUFA date 2024 July.
Emerging market	 Hong Kong and Pakistan agreement signed Discussion ongoing

 Licensing-out for other self-development injectable products are ongoing



